DGAP-News: sterna biologicals GmbH & Co. KG / Key word(s): Study/Miscellaneous14.12.2021 / 14:00 The issuer is solely responsible for the content of this announcement.STERNA BIOLOGICALS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE IIA PROOF-OF-CONCEPT STUDY WITH SB010 IN MODERATE TO SEVERE ASTHMA GIANT-1 study to eva.
DGAP-News: sterna biologicals GmbH & Co. KG / Key word(s): Study/Miscellaneous sterna biologicals announces dosing of first patient in phase IIa proof-of-concept study with SB010 in moderate to severe asthma 14.12.2021 / 14:00 The issuer is solely responsible for the content of this announce.